secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001193125-23-135024
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir reports Q1 net loss $41.2M; Phase 3 posoleucel trials on track for 2024
-------------------------------------------------------------------------------

- Net loss of $41.2M ($0.44/share) vs $43.9M ($0.69/share) in Q1 2022.
- Cash, cash equivalents and short-term investments were $202.6M as of March 31, 2023.
- R&D expenses $30.7M, G&A $12.5M; FY 2023 operating expense guidance $150M-$170M excl. non-cash.
- Three Phase 3 registrational trials of posoleucel in allo-HCT patients continue enrolling; data readouts expected in 2024.
- Positive Phase 2 data for posoleucel in BK viremia in kidney transplant recipients to be presented at ATC 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312523135024/0001193125-23-135024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312523135024/d277750d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-135024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer